1 document found, page 1 of 1
Sort by
Issue Date
Pre-operative exposure to tofacitinib is as safe as biologics in patients with ...
Dragoni, G.; Innocenti, T.; Amiot, A.; Castiglione, F.; Melotti, L.; Festa, S.; Savarino, E. V.; Truyens, M.; Argyriou, K.; Noviello, D.; Molnar, T.Patients with ulcerative colitis (UC) receiving immunomodulators are at substantial risk of colectomy. Since robust evidence regarding the post-operative outcomes of patients treated with anti-JAKs in the pre-operative phase is lacking, we aimed to assess the risk of complications of tofacitinib exposure prior to colectomy in comparison with anti-TNFs, vedolizumab, and ustekinumab.
Date: 2024
|
Origin: Sapientia - Universidade do Algarve